<?xml version="1.0" encoding="UTF-8" standalone="yes"?><drugRecordsOutput><serviceExecutionTime>310</serviceExecutionTime><Drug id="80605"><DrugName>epoetin alfa follow-on biologic, Fiocruz/Bio-Manguinhos</DrugName><DrugNamesKey><Name id="42758552">epoetin alfa</Name></DrugNamesKey><DrugSynonyms><Name><Value>epoetin alfa</Value><Types><Type>USAN</Type><Type>BAN</Type><Type>INN</Type></Types></Name><Name><Value>epoetin alfa follow-on biologic, Fiocruz/Bio-Manguinhos</Value></Name><Name><Value>alfaepoetina</Value></Name></DrugSynonyms><CompanyOriginator id="1059311">Bio-Manguinhos/Fiocruz</CompanyOriginator><CompaniesPrimary><Company id="1059311">Bio-Manguinhos/Fiocruz</Company></CompaniesPrimary><CrossReferences><SourceEntity id="17" type="ciIndication"><TargetEntity id="10002034" type="MEDDRA"/><TargetEntity id="D000740" type="MeSH"/><TargetEntity id="-201701473" type="omicsDisease"/><TargetEntity id="988" type="siCondition"/></SourceEntity><SourceEntity id="PTGT-03045" type="ciTarget"><TargetEntity id="92553377420563" type="siTarget">Erythropoietin</TargetEntity><TargetEntity id="245" type="omicsTarget"/></SourceEntity></CrossReferences><PhaseHighest id="L">Launched</PhaseHighest><PhaseHighestDetailed><FirstLaunched>Anemia - Brazil - Dec-2006</FirstLaunched></PhaseHighestDetailed><IndicationsPrimary><Indication id="17">Anemia</Indication></IndicationsPrimary><ActionsPrimary><Action id="12162">Erythropoietin ligand</Action></ActionsPrimary><ActionsSecondary><Action id="610">Hematopoietic stimulator</Action></ActionsSecondary><Technologies><Technology id="647">Subcutaneous formulation</Technology><Technology id="648">Intravenous formulation</Technology><Technology id="74">Glycoprotein</Technology><Technology id="761">Biological therapeutic</Technology><Technology id="85">Protein recombinant</Technology><Technology id="961">Follow on biological product</Technology></Technologies><LastModificationDate>2012-09-04T10:51:58.000Z</LastModificationDate><ChangeDateLast>2017-03-16T00:00:00.000Z</ChangeDateLast><AddedDate>2012-08-28T00:00:00.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkType="Company" linkID="1059311"&gt;Fiocruz/Bio-Manguinhos&lt;/ulink&gt; has developed and launched  alfaepoetina, a follow-on biologic version of the recombinant human erythropoietin (rhEPO) &lt;ulink linkType="Drug" linkID="6797"&gt;epoetin alfa&lt;/ulink&gt;, produced in CHO cells, for the iv or sc treatment of anemia caused by chronic renal insufficiency, anemia in AIDS patients receiving &lt;ulink linkType="Drug" linkID="44316"&gt;zidovudine&lt;/ulink&gt; therapy, and chemotherapy-induced anemia. By December 2006, the product had been launched in Brazil   [&lt;ulink linkType="Reference" linkID="1317390"&gt;1317390&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;In April 2008, a randomized, double-blind, placebo-controlled, phase III trial (NCT01184495; 06-168) started to compare the efficacy of the Fiocruz/BioManguinhos product with that of an epoetin alfa biosimilar produced by a private company, both administered sc in patients (n = 74) in Brazil with chronic renal failure on hemodialysis. The trial completed in January 2009 [&lt;ulink linkType="Reference" linkID="1319450"&gt;1319450&lt;/ulink&gt;].&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="1059311">Bio-Manguinhos/Fiocruz</Company><Country id="BR">Brazil</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="17">Anemia</Indication><StatusDate>2006-12-31T00:00:00.000Z</StatusDate><Source id="1317390" type="CORPORATE"/></DevelopmentStatusCurrent></IDdbDevelopmentStatus><Targets><Target id="PTGT-03045"><Name>Erythropoietin ligand</Name><SwissprotNumbers><Swissprot>P01588</Swissprot><Swissprot>P07321</Swissprot><Swissprot>P07865</Swissprot><Swissprot>P29676</Swissprot><Swissprot>P33707</Swissprot><Swissprot>P33708</Swissprot><Swissprot>P33709</Swissprot><Swissprot>P48617</Swissprot><Swissprot>P49157</Swissprot><Swissprot>Q28513</Swissprot><Swissprot>Q867B1</Swissprot><Swissprot>Q9GKA2</Swissprot></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Indexing Updated</Reason><Description>Indexing updated</Description></ReasonForUpdate><ReasonForUpdate><Reason>Editorial Amendments</Reason><Description>Minor editorial amendment</Description></ReasonForUpdate></ReasonsForUpdate><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="3">Component of Combination</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="4">Delivery device</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="5">Formulation</Type><Count>2</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="8">General interest</Type><Count>2</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="9">New use</Type><Count>1</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="ANALIZA Inc" id="1004873"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Chung Shan Medical University" id="1031584"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Raygene Biotech International Inc" id="1138425"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Johnson &amp; Johnson" id="17332"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Novo Nordisk A/S" id="18614"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Roche Holding AG" id="19446"/><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="University Of Massachusetts" id="20615"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="University of Louisville" id="21246"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Deutsches Krebsforschungszentrum" id="23844"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Neose Technologies Inc" id="24203"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></Drug></drugRecordsOutput>